Announcing a new article publication for Cardiovascular Innovations and Applications journal. ACEI therapy decreases mortality in patients with acute MI.
Researchers explored existing literature on long coronavirus disease (COVID). They highlighted key immunological findings, similarities with other diseases, symptoms, and associated pathophysiological mechanisms, and diagnostic and therapeutic options, including COVID-19 vaccinations.
Researchers presented a microbody recombinant decoy protein with high affinity to angiotensin-converting enzyme 2 (ACE2) as an option for coronavirus disease 2019 (COVID-19) treatment.
In a recent study published in the BMJ, researchers conducted a phase three, multicenter, randomized controlled trial to evaluate the effect of using angiotensin receptor blockers that disrupt the renin-angiotensin system on the clinical outcomes of individuals with coronavirus disease 2019 (COVID-19).
In lab studies on rats, they found that when compared to the young mice without hypertension, the young mice with induced hypertension had a significant 24 per cent reduction in bone volume fraction.They